BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• 

  Research Roundup: A Potential Treatment for Metabolic Syndrome and Affimed’s NK Combo

  Typical metabolic syndrome treatment includes a healthy diet, exercise, and possibly metformin, but soon, there may be a new treatment. For that and more research news, continue reading.

  April 14, 2022

   · 

  5 min read

   · 

  Mark Terry
• 

  Roche Wakes Up to New Competition as FDA Approves Amneal’s Avastin Biosimilar

  Amneal Pharmaceuticals received the green light from the U.S. Food and Drug Administration for bevacizumab-maly, a biosimilar to Genentech (Roche)’s Avastin.

  April 14, 2022

   · 

  2 min read

   · 

  Alex Keown
• 

  Mayo Researchers Combine CAR-T and Oncolytic Virus in New Attack on Cancer

  Researchers are combining CAR-T cell therapy with cancer-killing viruses to create an even more potent treatment against solid cancer tumors.

  April 14, 2022

   · 

  2 min read

   · 

  Hayley Shasteen
• 

  Drug Development

  Merck’s Pneumococcal Vaccine Claims FDA Breakthrough Therapy Designation

  The FDA granted Merck’s investigational 21-valent pneumococcal conjugate vaccine (V116) for IPD and pneumococcal pneumonia Breakthrough Therapy Designation.

  April 14, 2022

   · 

  3 min read

   · 

  Mark Terry
• 

  Drug Development

  Highlights from AACR’s Final Day: Mustang Bio, ChemoCentryx, Allogene and More

  The AACR annual meeting concluded on April 13, showcasing hundreds of preclinical to late-stage information from ongoing studies on treatment candidates.

  April 14, 2022

   · 

  4 min read

   · 

  Vanessa Doctor, RN
• 

  Drug Development

  Protagonist’s PV Breakthrough Designation on the Line

  Protagonist disclosed the FDA issued a letter of intent to rescind the status for rusfertide based on concerns first raised in a clinical hold placed on the drug.

  April 14, 2022

   · 

  2 min read

   · 

  Alex Keown
• 

  Drug Development

  Pfizer, BioNTech Seek Approval for Boosters in Children Following Positive Data

  Pfizer and BioNTech will submit updated data to the FDA to support the Emergency Use Authorization (EUA) of COVID-19 vaccination boosters in children between the age of 5 and 11.

  April 14, 2022

   · 

  2 min read

   · 

  Jazmine Colatriano, M.S.
• 

  Business

  Gilmore O’Neill “Excited” to Take the Reins at Editas Medicine

  O’Neill, who has served as chief medical officer at Sarepta Therapeutics since 2018, said he is excited about the potential of Editas’ pipeline.

  April 14, 2022

   · 

  4 min read

   · 

  Alex Keown
• 

  Business

  AACR: Philip Kantoff Discusses Convergent’s Unique Path to Treating Prostate Cancer

  Philip Kantoff, CEO of Convergent Therapeutics, spoke to BioSpace before the American Association for Cancer Research Annual Meeting on April 8-13 about CONV01-α.

  April 14, 2022

   · 

  6 min read

   · 

  Gail Dutton
• 

  Business

  Biopharma Companies Unite in Partnerships Against Cancer, IBD

  Ubix Therapeutics has announced a collaboration agreement with SK Biopharmaceuticals, and Engitix and Takeda are teaming up to develop a therapeutic for fibrostenotic IBD.

  April 14, 2022

   · 

  3 min read

   · 

  Jazmine Colatriano, M.S.